| Hazard Information | Back Directory | [Uses]
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells[1]. | [in vivo]
Mupadolimab (10 mg/kg; i.p.; daily for 15 days) stimulates antigen specific humoral immunity in SARS-CoV-2 infected NSG-SGM3 mice[1]. | Animal Model: | NSG-SGM3 mice, immunized with an emulsion of 50 μg full length spike protein from SARS-CoV-2 and Freund’s Incomplete Adjuvant subcutaneously on both the left and right flank (25 μg/side)[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection, daily for 15 days | | Result: | Mice treated with the drug made antibodies to the immunizing TS protein; but not to the control nucleocapsid SARS-CoV-2 viral protein. |
| [storage]
Store at -20°C | [References]
[1] Miller R A, et al. Clinical results with a B cell activating anti-CD73 antibody for the immunotherapy of Covid-19. medRxiv, 2021. |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|